Column charts of SI_8min and SI_10min in the therapy and control group at follow-up. by Felix L. Herr (21544362)

Representative CEUS images with BR55 of mice with a subcutaneous tumour allograft (arrows) under treatment. by Felix L. Herr (21544362)

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

The ANCOVA and Post_hoc results. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

Time to stabilization in the vertical direction. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

The description of games. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

The description of balance training. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

Comparison within groups. by Neng Pan (5262032)

Comparison of data after the experiment. by Neng Pan (5262032)

Baseline characteristics. by Neng Pan (5262032)

“…In the ST group alone, significant enhancements were noted in parameters including walking speed (GS) and hand strength on the left side (HS-L). …”

Data ste. by Neng Pan (5262032)

“…In the ST group alone, significant enhancements were noted in parameters including walking speed (GS) and hand strength on the left side (HS-L). …”

Comparison of post-experimental outcome measures. by Neng Pan (5262032)

“…In the ST group alone, significant enhancements were noted in parameters including walking speed (GS) and hand strength on the left side (HS-L). …”